治疗急性髓系白血病/高危骨髓增生异常综合征新药：新型Hedgehog信号通路抑制剂glasdegib
[20] Cortes JE， Douglas Smith B， Wang ES， et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS： phase 2 study results[J]. Am J Hematol， 2018， 93(11)： 1301-1310.
[21] Wagner AJ， Messersmith WA， Shaik MN， et al. A phase I study of PF-04449913， an oral hedgehog inhibitor， in patients with advanced solid tumors[J]. Clin Cancer Res， 2015， 21(5)： 1044-1051.
[22] Jamieson C， Cortes JE， Oehler V， et al. Phase 1 doseescalation study of PF-04449913， an oral hedgehog (Hh) inhibitor， in patients with select hematologic malignancies[J]. Blood， 2011， 118(21)： 424. doi： 10.1182/blood.V118.21.424.424.
[23] Borate U， Smith BD， Gore S， et al. Phase 1b study of glasdegib (PF-04449913) in combination with azacitidine in patients with higher risk myelodysplastic syndrome， oligoblastic acute myeloid leukemia， or chronic myelomonocytic leukemia[J]. Haematologica， 2016， 101(S1)： 73-74.
[24] Cortes JE， Dombret H， Merchant AA， et al. Phase 3， randomized， placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia[J/OL]. J Clin Oncol， 2018， 36(15 Suppl)： TPS7073-TPS7073. doi： 10.1200/ JCO.2018.36.15, 百拇医药(邢燕 王春晖 吕迁洲)
[21] Wagner AJ， Messersmith WA， Shaik MN， et al. A phase I study of PF-04449913， an oral hedgehog inhibitor， in patients with advanced solid tumors[J]. Clin Cancer Res， 2015， 21(5)： 1044-1051.
[22] Jamieson C， Cortes JE， Oehler V， et al. Phase 1 doseescalation study of PF-04449913， an oral hedgehog (Hh) inhibitor， in patients with select hematologic malignancies[J]. Blood， 2011， 118(21)： 424. doi： 10.1182/blood.V118.21.424.424.
[23] Borate U， Smith BD， Gore S， et al. Phase 1b study of glasdegib (PF-04449913) in combination with azacitidine in patients with higher risk myelodysplastic syndrome， oligoblastic acute myeloid leukemia， or chronic myelomonocytic leukemia[J]. Haematologica， 2016， 101(S1)： 73-74.
[24] Cortes JE， Dombret H， Merchant AA， et al. Phase 3， randomized， placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia[J/OL]. J Clin Oncol， 2018， 36(15 Suppl)： TPS7073-TPS7073. doi： 10.1200/ JCO.2018.36.15